AllSci News
Genetix expands gene therapy footprint into Middle East with SPIMACO manufacturing deal
Somerville, Massachusetts-based Genetix Biotherapeutics has struck an exclusive licensing and commercialization agreement with Saudi-based Saudi...
Gilead's Trodelvy becomes first ADC approved for first-line metastatic triple-negative breast cancer in EU
Gilead's sacituzumab govitecan (Trodelvy) has secured European Commission marketing authorization as a first-line monotherapy for metastatic triple-negative...
Susan G. Komen foundation issues USD 15.4m in grants for breast cancer research across 35 investigators
Susan G. Komen awards USD 15.4 million in breast cancer research grants
Pfizer's Seagen-acquired IB6 ADC fails primary survival test in advanced lung cancer
Pfizer (NYSE: PFE) reported that sigvotatug vedotin, an integrin beta-6 (IB6)-directed antibody-drug conjugate, failed to demonstrate a statistically...
BMS-partnered iza-bren becomes world’s first approved bispecific ADC with China NPC nod
China has issued a market approval for iza-bren (izalontamab brengitecan; BL-B01D1) as a treatment for nasopharyngeal carcinoma (NPC), marking the first regulatory…
Merck's tulisokibart becomes first anti-TL1A antibody to achieve Phase III remission in ulcerative colitis
Merck (NYSE: MRK) reported positive topline results from the Phase III ATLAS-UC Study 2, making tulisokibart (MK-7240) the first anti-TL1A monoclonal...
MoonLake raises USD 150m to commercialize sonelokimab ahead of hidradenitis suppurativa BLA filing
Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) announced a proposed public offering of USD 150 million in Class A ordinary shares — with...
uniQure raises USD 150m after positive FDA signal on Huntington's disease therapy
Lexington, Massachusetts-based uniQure N.V. (Nasdaq: QURE) announced a proposed underwritten public offering of ordinary shares and pre-funded warrants...
Lilly closes USD 7.8 billion Centessa deal, enters sleep-wake disorder market with OX2R pipeline
The High Court of Justice of England and Wales has sanctioned the scheme of arrangement implementing Eli Lilly's acquisition of Centessa Pharmaceuticals plc...
Pierre Fabre’s Braftovi becomes first targeted therapy approved for BRAF-mutant colorectal cancer in Europe
France-based Laboratoires Pierre Fabre has received European Commission approval for Braftovi (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin)…
Sanofi wins EU approval for Cenrifki in non-relapsing SPMS despite FDA rejection
The European Commission has approved Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the last two years,…
Orion secures EU orphan designation for Hippo pathway-targeted ODM-212 in mesothelioma
Finland-based Orion Oyj (Helsinki: ORNBV) announced receipt of orphan designation from the European Commission for ODM-212 in malignant mesothelioma, based on a…
AbbVie expands Skyrizi into pediatric psoriasis with new weight-based formulation
The European Commission has approved Skyrizi (risankizumab) for children and adolescents aged six years and older with moderate to severe plaque psoriasis…
Novartis advances FAP theranostic platform with first-in-human imaging agent trial across six solid tumors
Novartis has initiated a first-in-human Phase I trial of [68Ga]Ga-DFC413 (JFI447), a gallium-68-labeled radioligand designed to image fibroblast activation...
China approves first CAR-T therapy for a solid tumor with CARsgen’s Satri-cel
China’s NMPA has approved Satri-cel (satricabtagene autoleucel) for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least…
The AllSci Brief
Systematic R&D and deal news. Daily.